A multi-institutional team of researchers at the University of Toronto has unveiled a next-generation RNA therapeutic platform designed to target…
Read More
SpliSense Advances Promising Cystic Fibrosis Therapy with Significant Funding and Phase IIb Trial Launch
The biotech firm SpliSense is making significant strides in the development of a novel therapy for cystic fibrosis, announcing a…
Read More
Simcere Pharmaceutical Group Partners with Stanford Medicine to Pioneer Novel Therapies for Idiopathic Pulmonary Fibrosis
Simcere Pharmaceutical Group has forged a significant research collaboration with Stanford Medicine, aiming to unlock novel therapeutic avenues for idiopathic…
Read More
Japan Approves Jascayd (nerandomilast) for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Boehringer Ingelheim has achieved a significant milestone in the treatment of interstitial lung diseases with the approval of Jascayd (nerandomilast)…
Read More
AI-Powered "GPS" Model Marks Paradigm Shift in Drug Discovery, Identifies Candidates for Liver Cancer and Pulmonary Fibrosis
A groundbreaking machine-learning model, dubbed "GPS" (Gene Expression Profile Predictor on Chemical Structures), has been unveiled by a multi-institute collaboration…
Read More
